Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma

Li Chun Lu, Chiun Hsu, Yu Yun Shao, Yee Chao, Chia Jui Yen, I. Lun Shih, Yi Ping Hung, Chun Jung Chang, Ying Chun Shen, Jhe Cyuan Guo, Tsung Hao Liu, Chih Hung Hsu, Ann Lii Cheng

研究成果: Article

1 引文 斯高帕斯(Scopus)

摘要

Background and Aims: Immune checkpoint inhibitors (ICIs) exhibit significant clinical activity in patients with advanced hepatocellular carcinoma (HCC). This study explored whether tumor response to ICIs in HCC varies among different organs. Methods: We reviewed the data of patients with advanced HCC who had received ICIs. Patients with measurable diseases were enrolled. Organ-specific response criteria, adapted from RECIST 1.1 and immune-related RECIST, were used to evaluate the objective response to ICIs in tumors located in the liver, lung, lymph node, and other intra-abdominal sites. Results: Of the 75 enrolled patients with advanced HCC, 51 and 11 patients had chronic hepatitis B virus and chronic hepatitis C virus infection, respectively. Regarding ICI treatment, 58, 1, and 16 patients had undergone anti-PD-1/anti-PD-L1 monoclonal antibody (mAb) alone, anti-CTLA4 mAb alone, and anti-PD-1 mAb plus anti-CTLA4 mAb, respectively; 20 and 55 patients had received ICIs as first-line or ≥second-line therapy. The overall objective response rate (ORR) was 28.0%. In total, 58, 34, 19, and 18 patients had measurable hepatic tumors and lung, lymph node, and other intra-abdominal metastases, and the corresponding organ-specific ORRs were 22.4, 41.2, 26.3, and 38.9%, respectively. Of the 39 patients who had both hepatic and extrahepatic tumors, 12 had disease control in extrahepatic tumors while progressive disease (PD) in hepatic tumors, whereas only 4 exhibited disease control in hepatic tumors while PD in extrahepatic tumors (p = 0.046, McNemar test). Of the 16 patients with only evaluable tumors in the liver and lungs at baseline, 8 had disease control in the lungs while PD in the liver, and none experienced disease control in the liver while PD in the lungs (p = 0.005). Conclusions: The hepatic tumors of HCC may be less responsive to ICIs than extrahepatic lesions. Lung metastases responded most favorably to ICIs. The mechanisms underlying this differential response to ICIs warrant further investigation.

原文English
頁(從 - 到)480-490
頁數11
期刊Liver Cancer
8
發行號6
DOIs
出版狀態Published - 2019 十一月 1

    指紋

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Oncology

引用此

Lu, L. C., Hsu, C., Shao, Y. Y., Chao, Y., Yen, C. J., Shih, I. L., Hung, Y. P., Chang, C. J., Shen, Y. C., Guo, J. C., Liu, T. H., Hsu, C. H., & Cheng, A. L. (2019). Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Liver Cancer, 8(6), 480-490. https://doi.org/10.1159/000501275